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Comparison of monocyte human leukocyte
antigen-DR expression and stimulated
tumor necrosis factor alpha production as
outcome predictors in severe sepsis: a
prospective observational study
Anne M. Drewry1*, Enyo A. Ablordeppey2, Ellen T. Murray3, Evan R. Beiter1, Andrew H. Walton1, Mark W. Hall4
and Richard S. Hotchkiss1
Abstract
Background: Identifying patients in the immunosuppressive phase of sepsis is essential for development of
immunomodulatory therapies. Little data exists comparing the ability of the two most well-studied markers of
sepsis-induced immunosuppression, human leukocyte antigen (HLA)-DR expression and lipopolysaccharide
(LPS)-induced tumor necrosis factor alpha (TNF-ɑ) production, to predict mortality and morbidity. The purpose
of this study was to compare HLA-DR expression and LPS-induced TNF-ɑ production as predictors of 28-day
mortality and acquisition of secondary infections in adult septic patients.
Methods: A single-center, prospective observational study of 83 adult septic patients admitted to a medical or
surgical intensive care unit. Blood samples were collected at three time points during the septic course (days 1–2, days
3–4, and days 6–8 after sepsis diagnosis) and assayed for HLA-DR expression and LPS-induced TNF-ɑ production. A
repeated measures mixed model analysis was used to compare values of these immunological markers among
survivors and non-survivors and among those who did and did not develop a secondary infection.
Results: Twenty-five patients (30.1 %) died within 28 days of sepsis diagnosis. HLA-DR expression was significantly lower
in non-survivors as compared to survivors on days 3–4 (p = 0.04) and days 6–8 (p = 0.002). The change in HLA-DR from
days 1–2 to days 6–8 was also lower in non-survivors (p = 0.04). Median HLA-DR expression decreased from days 1–2 to
days 3–4 in patients who developed secondary infections while it increased in those without secondary infections (p = 0.
054). TNF-ɑ production did not differ between survivors and non-survivors or between patients who did and did not
develop a secondary infection.
Conclusions: Monocyte HLA-DR expression may be a more accurate predictor of mortality and acquisition of
secondary infections than LPS-stimulated TNF-ɑ production in adult medical and surgical critically ill patients.
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Background
Sepsis-induced immunosuppression is a term used to de-
scribe the immunosuppressive phenotype that develops in
many patients with protracted sepsis. It is characterized by
numerous abnormalities in the innate and adaptive im-
mune systems including increased immune cell apoptosis,
impaired phagocytosis, diminished antigen-presenting
ability, and dysregulated cytokine production [1]. Septic
patients with these abnormalities are less able to eliminate
primary infections and are more susceptible to secondary
nosocomial infections, including those caused by oppor-
tunistic organisms [2].
Greater appreciation for the role of immune dysfunction
in sepsis mortality has led to clinical trials of immuno-
modulatory agents that stimulate the immune system.
Early evidence from these trials has been encouraging.
Granulocyte-macrophage colony-stimulating factor (GM-
CSF), a cytokine that activates neutrophils and monocytes,
has been shown to reverse features of sepsis-induced im-
munosuppression and improve clinical outcomes such as
hospital length of stay and acquisition of nosocomial in-
fections [3, 4]. Interferon gamma (IFN- ), also a potent
monocyte activator, decreased time to fungal clearance in
a randomized trial of HIV patients with cryptococcal men-
ingitis [5]. Other potential immunotherapy agents, such as
anti-programmed cell death ligand 1 (PD-L1) antibody
and interleukin 7 (IL-7), have shown benefit in animal
models of sepsis and are currently being tested in clinical
trials [6, 7].
Immune responses during sepsis can vary among pa-
tients and evolve over the course of the illness. Ideally,
only patients with features of immunosuppression
should be treated with immunostimulatory agents to
avoid potential harm in patients with already robust pro-
inflammatory responses. Multiple assays for markers of
immunosuppressive mechanisms have been developed to
identify these patients [8, 9]. Two of the most well-
studied markers of immunosuppression are ex vivo lipo-
polysaccharide (LPS)-induced tumor necrosis factor
alpha (TNF-ɑ) production, which is a functional test of
monocytic immune capacity, and monocyte cell surface
expression of human leukocyte antigen (HLA)-DR. De-
creased levels of TNF-ɑ production and HLA-DR ex-
pression indicate monocyte dysfunction and have been
associated with an increased risk of nosocomial infec-
tions and death in critically ill patients [10–14]. Each of
these markers has previously been used in clinical trials
to identify patients who are at higher risk for morbidity
and mortality in sepsis and who therefore might benefit
from immunomodulatory therapy [3, 4].
While several studies have independently evaluated
these markers in sepsis survivors and non-survivors, lit-
tle data exist directly comparing the ability of HLA-DR
expression and LPS-induced TNF-ɑ production to
predict morbidity or mortality in adult septic patients
[15–18]. Thus, the aim of this study was to determine
which of these tests is most predictive of 28-day mortal-
ity and of acquisition of secondary infections in critically
ill adult patients with severe sepsis.
Methods
Study design
This was a prospective observational study and is re-
ported in accordance with the Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE)
guidelines [19]. It was approved by the institutional Hu-
man Research Protections Office. Informed consent was
obtained from all individual participants or their legally
authorized representatives.
Study setting and population
This study was conducted in the medical and surgical
intensive care units (ICUs) of a 1200-bed university-
affiliated tertiary care center between August 1, 2014
and May 31, 2015. Adult patients admitted to the ICU
with a new diagnosis of severe sepsis within 48 hours
were screened for inclusion. Severe sepsis was defined
according to consensus criteria [20]. Exclusion criteria
included: history of immunological disease, treatment
with immunosuppressive medications within the previ-
ous 3 months, treatment with therapeutic hypothermia,
and chronic infection with hepatitis B or C virus. Pa-
tients transferred to the institution from other hospitals
with a diagnosis of sepsis were also excluded because
the exact time of sepsis diagnosis could not be con-
firmed. Detailed inclusion and exclusion criteria are
listed in Additional file 1.
Data collection and clinical outcomes
Baseline demographics included age, sex, source of sep-
sis, presence of co-morbidities, Acute Physiology and
Chronic Health Evaluation (APACHE) II score, and Se-
quential Organ Failure Assessment (SOFA) score.
Microbiology data were collected for each positive cul-
ture. The primary outcome was 28-day mortality. The
secondary outcome was acquisition of secondary infec-
tions. Secondary infections were defined as infections di-
agnosed by the treating physicians between 3 and
30 days after the primary sepsis diagnosis that required a
new course of antibiotics for at least 5 days. The site of
the secondary infection was determined by the presence
of positive culture data or documentation in the medical
record by the treating physicians.
Immunological data
Blood samples were collected during three time periods
for each patient, days 1–2 (time point A), days 3–4 (time
point B), and days 6–8 (time point C) after sepsis
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diagnosis. The first 24-hour time period following the
sepsis diagnosis time was considered to be day 1; the
next 24-hour period, day 2; etc. These samples were
tested for monocyte HLA-DR expression and LPS-
induced TNF-ɑ production by blinded research assis-
tants. Once patients were discharged from the ICU, sub-
sequent blood samples were not collected. Additionally,
leukocyte counts from complete blood cell counts
(CBCs) ordered by the treating physicians were recorded
for the first 7 days following sepsis diagnosis.
Quantification of monocyte HLA-DR
Quantification of monocyte HLA-DR was performed
according to the methods of Demaret et al. [21]. Briefly,
whole blood was incubated with BD Quantibrite Anti-
HLA-DR/Anti-Monocyte Stain (Becton Dickinson, San
Jose, CA, USA), lysed using RBC Lysis Buffer (BioLegend,
San Diego, CA, USA), and fixed in 2 % paraformaldehyde.
Samples were acquired on a FACScan (Becton Dickinson,
San Jose, CA, USA) with a five-color upgrade (CyTech,
Fremont, CA, USA). Flow files were acquired and ana-
lyzed in CellQuest Pro (Becton Dickinson, San Jose, CA,
USA). Antibodies bound per cell (ABC) were calculated
by standardizing HLA-DR geometric mean fluorescence
intensity (GMFI) of monocytes to BD Quantibrite-
phycoerythrin (PE) beads (Becton Dickinson, San Jose,
CA, USA) (Fig. 1).
Quantification of LPS-induced TNF-ɑ production
LPS-stimulated whole blood TNF-ɑ production was per-
formed according to the methods described by Hall et al.
[4]. Patient blood was collected in sterile heparinized tubes
and transferred to the laboratory within 5–15 minutes.
Fifty microliters of whole blood was added to microcentri-
fuge tubes containing 0.5 mL RPMI-1640 fortified with
10 % fetal bovine serum, penicillin-streptomycin, non-
essential amino acids, and either plus or minus 0.5 ng/mL
LPS. The tubes were incubated at 37 °C for 4 hours. Su-
pernatants were then removed and stored at -80 °C until
enzyme-linked immunosorbent assays (ELISA) were per-
formed for TNF-α production. All samples were run in
duplicate. Additionally, a control population of five
healthy volunteer adults was tested for TNF-α production.
Statistical analysis
Descriptive statistics, including mean and standard devi-
ation (SD) for normally distributed data or median and
interquartile range (IQR) for non-normally distributed data,
were used to describe the patient cohort. Normality was
assessed using histograms and the Kolmogorov-Smirnov
test. Comparisons of baseline characteristics in 28-day sur-
vivors and non-survivors were assessed using independent
samples t tests, Mann-Whitney U tests, chi-square tests, or
Fisher’s exact tests, as appropriate.
Analyses of HLA-DR expression and TNF-ɑ production


































Fig. 1 Gating strategy for determining monocyte HLA-DR levels. A monocyte gate was created by first gating upon forward and side scatter cell
properties (upper right panel) and then further refining the monocyte gate by determining positivity for CD14 (lower left panel). Geometric mean
fluorescence intensity (GMFI) data were then collected from the monocyte population in the HLA-DR channel (PE) (lower right panel) and compared
against a Quantibrite Bead Reference (Becton Dickinson, San Jose, CA, USA) (upper left panel) to yield average per cell HLA-DR intensity. HLA human
leukocyte antigen, PE phycoerythrin
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The primary focus of these analyses was on the signifi-
cance of interactions that tested hypotheses regarding
equality of changes over time in 28-day survivors and
non-survivors and in those with and without a secondary
infection. The appropriate statistical contrasts were used
to test the null hypotheses that: (a) values at time points
A, B, and C were equal between the groups; (b) change in
values between time point A and time point B were equal
between the groups; and (c) change in values between
time point A and time point C were equal between the
groups. These contrasts were not adjusted for multiple
comparisons. Additionally, correlation between HLA-DR
expression and LPS-induced TNF-ɑ production at each
time point were evaluated with Pearson correlation after
log transformation of the data.
Results
A total of 85 patients were enrolled after screening 271
patients with severe sepsis (Fig. 2). Two patients, one
who was found to be a screen failure and another who
was determined not to be infected following enrollment,
were subsequently excluded from analysis.
Twenty-five patients (30.1 %) died within 28 days of sep-
sis diagnosis. Table 1 reports the baseline characteristics
for survivors and non-survivors. Non-survivors had more
severe disease than survivors as measured by APACHE II
score (mean 22.6 [SD 5.8] vs 18.2 [5.0], p < 0.001) and
SOFA score (mean 8.6 [SD 3.2] vs 6.9 [2.4], p = 0.009).
There were no significant differences between the two
groups in terms of age, gender, source of sepsis, propor-
tion of patients with positive cultures, or type of infecting
organism. Details regarding timing of blood sampling and
reasons for missing samples in survivors and non-
survivors are shown in Additional file 2. The median time
from sepsis diagnosis until blood collection was not sig-
nificantly different between the groups at any time point.
Leukocyte counts in each group for the first 7 days after
sepsis diagnosis are shown in Additional file 3.
Figure 3a shows median and interquartile range of
HLA-DR expression at each of the three time points
(days 1–2 [A], days 3–4 [B], and days 6–8 [C]) in 28-day
survivors and non-survivors. Table 2 shows results of
the mixed models analysis comparing median HLA-DR
expression at each time point and the median change in
HLA-DR expression from time point A to time point B
and from time point A to time point C between survi-
vors and non-survivors. Survivors had significantly
higher expression of HLA-DR at time point B (median
11,351 [IQR 4316, 18,417] antibodies (AB)/cell vs 5895
[2900, 10,388] AB/cell, p = 0.04) and at time point C
(median 14,470 [7656, 17,906] AB/cell vs 6195 [3721,
9662] AB/cell, p = 0.002). Likewise, compared to non-
survivors, survivors had a significantly greater increase
in HLA-DR expression between time points A and C (p
= 0.04). The change in HLA-DR expression between
time points A and B was not statistically significant (p =
0.34). Septic patients had significantly lower TNF-ɑ pro-
duction compared to healthy controls (median 195 [IQR
79, 373] pg/ml vs median 595 [IQR 500, 1302] pg/ml, p
= 0.004). There were no significant differences in TNF-ɑ
production at any time point between survivors and
non-survivors (Fig. 3b and Table 2). The change in me-
dian TNF-ɑ production from time point A to B and
from time point A to C was also not significantly differ-
ent between the two groups (Table 2).
Twenty-two patients (26.5 %) developed a secondary in-
fection. The most common site of secondary infection was
the lung (nine patients), and the most common cultured
Patients with severe sepsis
screened for inclusion
n = 271
Treatment with immunosuppressive medications, n = 89
Transferred from another hospital, n = 40
History of chronic infection with HBV or HCV, n = 21
History of immunological disease, n = 18
Treatment with therapeutic hypothermia, n = 1
Unable to contact legal representative, n = 1
Declined to participate, n = 16
Enrolled
n = 85
Screen failure, n = 1

















Fig. 2 Flow diagram of included patients and reasons for patient exclusion. HBV hepatitis B virus, HBC hepatitis C virus
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organisms were Gram-negative bacteria (Additional file 4).
The median time to secondary infection onset was 9.4 days
(IQR 5.5, 19.0 days). Table 3 shows the mixed models ana-
lysis for HLA-DR expression and LPS-induced TNF-ɑ pro-
duction in patients who acquired secondary infections
versus those who did not. There were no significant differ-
ences in HLA-DR values between these two groups at any
of the three time points. However, patients who developed
secondary infections demonstrated an overall decrease in
HLA-DR expression from time point A to B (-934 [-6505,
353] AB/cell) while those who did not experienced an
increase in HLA-DR expression 918 ([-1242, 4132] AB/cell,
p = 0.54) (Fig. 3c and Table 3). There were no differences in
TNF-α production at any time point nor changes in TNF-α
production between time points A and B or between time
points A and C (Fig. 3d and Table 3).
Pearson correlation of log-transformed HLA-DR ex-
pression and LPS-induced TNF-ɑ production at time
point A was 0.33 (p = 0.007); B, 0.45 (p < 0.001); and C,
0.38 (p = 0.06) (Fig. 4).
Discussion
Investigators are employing a variety of methods to
immune-phenotype septic patients. Numerous studies
have shown that low monocyte HLA-DR expression iden-
tifies septic patients who are at higher risk for death or
secondary hospital-acquired infections [10, 11, 22, 23]. Al-
though not as extensively studied as monocyte HLA-DR
expression, LPS-stimulated whole blood TNF-α produc-
tion has also been used to identify immunosuppressed
septic patients. Compared to monocyte HLA-DR expres-
sion, stimulated whole blood TNF-α production has a the-
oretical advantage as an indicator of host immunity
because it is a reflection of actual cell function, i.e., the
ability of cells to produce a key cytokine involved in host
defense. Critically ill pediatric patients with persistently
low stimulated TNF-α production have been shown to be
more likely to acquire life-threatening infections, and im-
portantly, treatment with immune-adjuvant GM-CSF was
shown to cause a rapid improvement in stimulated TNF-α
production that was associated with prevention of nosoco-
mial infections [4, 14].
The purpose of the present study was to compare two
tests that are used to evaluate immune status in septic
patients. Results showed that quantification of monocyte
HLA-DR expression could discriminate between sepsis
survivors and non-survivors 3–4 days after sepsis onset,
but not at days 1–2. These results are consistent with
Monneret and associates who reported that only after
48 hours of sepsis duration did monocyte HLA-DR ex-
pression become predictive of survival [10]. We specu-
late that monocyte HLA-DR expression may not be
predictive at an early phase of sepsis because circulating
monocytes are likely recruited out of the bloodstream to
sites of active infection. After this initial phase, a steady
state phase may occur in which circulating monocytes
more accurately reflect the whole body state of immun-
ity. Results from this study also indicate that prediction
of nosocomial infections may be best achieved by asses-
sing changes in HLA-DR expression over time rather
than values at individual time points.
One potential explanation for the usefulness of mono-
cyte HLA-DR expression as a marker of immune status
is its dynamic nature. Cell surface expression of HLA-
DR is rapidly responsive to circulating levels of pro- and







Age (years), mean (SD) 60.3 (17.5) 63.2 (17.8) 0.50
Sex (male), n (%) 38 (65.5) 13 (52.0) 0.24
APACHE IIa, mean (SD) 18.2 (5.0) 22.6 (5.8) <0.001
SOFA scorea, mean (SD) 6.9 (2.4) 8.6 (3.2) 0.009
ICU type, n (%) 0.72
Medical 30 (51.7) 14 (56.0)
Surgical 28 (48.3) 11 (44.0)
Source of infection, n (%) 0.94
Lung 22 (37.9) 9 (36.0)
Abdomen 11 (19.0) 5 (20.0)
Urinary tract 8 (13.8) 5 (20.0)
Bone or soft tissue 7 (12.1) 1 (4.0)
Central line 3 (5.2) 1 (4.0)
Endocarditis 2 (3.5) 1 (4.0)
Undetermined 5 (8.6) 3 (12.0)
Culture positive, n (%) 35 (60.3) 14 (56.0) 0.71
Organism, n (%) 0.88
Gram-negative 14 (24.1) 7 (28.0)
Gram-positive 10 (17.2) 3 (12.0)
Mixed 7 (12.1) 2 (8.0)
Fungal 1 (1.7) 1 (4.0)
Viral 3 (5.2) 1 (4.0)
Co-morbidities, n (%)
Coronary artery disease 15 (25.9) 6 (24.0) 0.55
Cerebrovascular disease 9 (15.5) 1 (4.0) 0.13
Congestive heart failure 16 (27.6) 8 (32.0) 0.79
Diabetes 21 (36.2) 3 (12.0) 0.034
Chronic renal insufficiency 14 (24.1) 4 (16.0) 0.56
Liver disease 4 (6.9) 3 (12.0) 0.42
COPD 14 (24.1) 2 (8.0) 0.13
SD standard deviation, APACHE Acute Physiology and Chronic Health
Evaluation, SOFA Sequential Organ Failure Assessment, ICU intensive care unit,
COPD chronic obstructive pulmonary disease
aExcluding neurological component























































































































































Fig. 3 Median and interquartile range of (a) HLA-DR expression in survivors and non-survivors, (b) LPS-induced TNF-ɑ production in survivors and
non-survivors, (c) HLA-DR expression in those who did and did not develop secondary infections, and (d) LPS-induced TNF-ɑ production in those
who did and did not develop secondary infections. HLA human leukocyte antigen, TNF-ɑ tumor necrosis factor alpha
Table 2 Mixed models analysis of HLA-DR expression and LPS-induced TNF-ɑ production in 28-day survivors and non-survivors
Survivors, n = 58 Non-survivors, n = 25 p
HLA-DR expression (antibodies/cell),
median (IQR)















Δ Sample A to B 434 (-1710, 2921) -630 (-1795, 626) 0.34
Δ Sample A to C 1662 (-2645, 8118) 810 (-3382, 3507) 0.04
LPS-induced TNF-ɑ production (pg/ml),
median (IQR)















Δ Sample A to B 0 (-130, 54) 20 (-23, 89) 0.27
Δ Sample A to C 16 (-112, 85) 29 (-85, 141) 0.56
HLA-DR human leukocyte antigen-DR, LPS lipopolysaccharide, TNF-ɑ tumor necrosis factor alpha, IQR 25 %, 75 % interquartile range
aDays after sepsis diagnosis
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anti-inflammatory cytokines, which are essential in
modulating the host response in sepsis. IL-6 and IL-10
cause downregulation of monocyte HLA-DR expression
while, conversely, IL-12 and IFN-γ cause increased
HLA-DR expression [24–26]. Also, HLA-DR plays a key
role in T cell activation. Decreased HLA-DR expression
may therefore result in less robust T cell stimulation and
resultant reduced T cell cytokine production, prolifera-
tion, and cytotoxicity.
Although LPS-induced TNF-α production and HLA-
DR expression were statistically correlated with each
other, LPS-induced TNF-ɑ production was not signifi-
cantly associated with mortality or acquisition of noso-
comial infections at any measured time point. The lack
of association between early LPS-induced TNF-α pro-
duction and subsequent nosocomial infections is consist-
ent with a previous study performed in critically ill
adults [27]. The present study also showed that the
TNF-α release assay conducted at later time points failed
to predict clinical outcomes. There are several possible
reasons for these results. The median value for TNF-α
in septic patients was less than 250 pg/ml at every mea-
sured time point (except days 6–8 in the survivors), and
the median value in healthy controls was lower than has
been reported in previous studies [13, 18]. The narrower
response range to LPS may have affected the ability to
discriminate between survivors and non-survivors. Also,
LPS-induced TNF-α production has primarily been
Table 3 Mixed models analysis of HLA-DR expression and LPS-induced TNF-ɑ production in septic patients who did and did not
develop a secondary infection
Secondary infection absent, n = 61 Secondary infection present, n = 22 p
HLA-DR expression (antibodies/cell),
median (IQR)















Δ Sample A to B 918 (-1242, 4132) -934 (-6505, 353) 0.054
Δ Sample A to C 3621 (-410, 9284) -1479 (-3382, 1662) 0.32
LPS-induced TNF-ɑ production (pg/ml),
median (IQR)















Δ Sample A to B -3 (-137, 55) 16 (-48, 65) 0.61
Δ Sample A to C 7 (-140, 97) 38 (-43, 120) 0.54
HLA-DR human leukocyte antigen-DR, LPS lipopolysaccharide, TNF-ɑ tumor necrosis factor alpha, IQR 25 %, 75 % interquartile range
































Fig. 4 Plot of correlation between log-transformed HLA-DR expression and LPS-induced TNF-ɑ production for each measured time point (days
1–2, days 3–4, and days 6–8). HLA human leukocyte antigen, TNF-ɑ tumor necrosis factor alpha
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studied in pediatric patients. There is increasing recogni-
tion of the impact of immunosenescence to blunt host
response to infection [28]. We speculate that the in-
creased age and high incidence of co-morbidities in this
study contributed to a blunted TNF-α response in both
survivors and non-survivors. TNF-α is largely produced
by monocytes, so absolute numbers may affect overall
TNF-α production. However, in the current study, survi-
vors tended to have lower absolute monocyte counts
than non-survivors, so this would not explain the low
TNF-α values seen in survivors.
Another potential explanation for the superiority of
HLA-DR expression over LPS-induced TNF-ɑ production
as a predictor of poor outcomes in the present study is the
differing degree to which these assays have been standard-
ized. Monocyte HLA-DR quantitation was historically
performed using flow cytometric methodology in which
percent positivity was determined in a subject’s sample by
comparison with a “negative” isotype control. Variability in
cytometer settings and lot-to-lot variability in
fluorochrome-labeled antibodies led to concern that the
threshold of 30 % HLA-DR positivity as a definition of se-
vere immunosuppression may not be generalizable between
cytometers and institutions. The Quantibrite method
employed in this study is also a flow cytometric test, but in
this case, the number of molecules of HLA-DR per mono-
cyte is calculated by comparing HLA-DR fluorescence in
an antibody-labeled sampled with a set of standard beads
with known HLA-DR expression. The use of standard
beads reduces variability and has been shown to yield highly
reproducible results across cytometers and institutions [29].
This is further evidenced by the fact that the HLA-DR
values obtained in the present study are comparable to
those previously published for similar septic cohorts [3, 30].
In contrast, LPS-induced TNF-ɑ production assays are
more difficult to standardize. Recent data shows that inter-
laboratory methodological variation (e.g., sample handling
prior to stimulation, LPS source, LPS concentration, incu-
bation time, etc.) impairs reproducibility and interpretation
of results [31]. Increased standardization of this assay may
improve the predicative performance of this biomarker.
Another key difference between these two assays is that
the flow cytometry HLA-DR expression assay is specific to
monocytes whereas the TNF-α production assay is per-
formed using whole blood and thus evaluates the capacity
of various cells to produce TNF-α in response to LPS. Al-
though monocytes account for the majority of TNF-α pro-
duction, lymphocytes and polymorphonuclear can produce
TNF-α and other cytokines in significant amounts [32].
This may lead to increased variability in the TNF-α produc-
tion assay as compared to HLA-DR expression assay.
Ultimately, sepsis-induced immunosuppression may be
best diagnosed by assessing a combination of various bio-
markers and clinical factors. In a recent study, monocyte
PD-L1 expression, another potential marker of immune
function, was found to accurately discriminate between 28-
day survivors and non-survivors of sepsis, and its prognos-
tic value was increased when assessed in combination with
traditional predictors of mortality such as the SOFA score
and Simplified Acute Physiology Score (SAPS) II score [33].
This study has several limitations. As expected, severity
of illness differed among survivors and non-survivors, so it
is not possible to conclude that HLA-DR expression is an
independent predictor of mortality based on these results.
Nonetheless, our aim was to compare HLA-DR expression
and stimulated TNF-ɑ production as markers of mortality,
which was achieved using univariable models. Also, while
we used a very similar approach to the measurement of
TNF-α response in recent pediatric studies, it is possible
that differences in reagent preparation and assay perform-
ance had an effect on our results. Another limitation was
that the number of patients included in analysis of time
point C (days 6–8 after sepsis diagnosis) was limited due to
patient death or discharge from the ICU. These missing
samples could potentially have biased our results. The con-
sistent upward trend in HLA-DR expression in survivors
from days 1–2 to days 6–8 as compared to a decrease seen
in non-survivors, however, supports the conclusion that
lower HLA-DR expression is predictive of mortality at this
later time point. TNF-α production, not found to be statis-
tically different among survivors and non-survivors in this
study, trends toward lower values in non-survivors on days
6–8. Perhaps, with greater statistical power, a significant dif-
ference would have been observed at this time point. Fi-
nally, this study does not address the ability of either of
these tests to predict which patients might respond best to
immunotherapy. Although patients with higher risks of
mortality and acquisition of secondary infections are opti-
mal targets for immunostimulatory therapy, the specific im-
munological tests best suited to specific therapies will need
to be tested in clinical trials.
Conclusions
The results of this study demonstrate that measurement
of monocyte HLA-DR expression was a more accurate
predictor of mortality and acquisition of nosocomial in-
fections than LPS-stimulated TNF-ɑ production in a
population of adult medical and surgical critically ill
septic patients. However, since functional testing repre-
sents the gold standard for evaluating immune function,
it is vitally important to improve performance and
standardization of these assays to fully evaluate their role
in the diagnosis of sepsis-induced immunosuppression.
Additional studies are needed to clarify which bio-
markers, or combinations of biomarkers, are potentially
most useful for identifying patients who might benefit
from immunotherapy.
Drewry et al. Critical Care  (2016) 20:334 Page 8 of 10
Additional files
Additional file 1: Detailed inclusion and exclusion criteria. (PDF 112 kb)
Additional file 2: Blood sampling details. (PDF 195 kb)
Additional file 3: Leukocyte counts in survivors and non-survivors for the
first 7 days following sepsis diagnosis. (PDF 97 kb)
Additional file 4: Characteristics of secondary infections. (PDF 10 kb)
Abbreviations
ABC: antibodies bound per cell; APACHE: Acute Physiology and Chronic
Health Evaluation; CBC: complete blood cell count; ELISA: enzyme-linked
immunosorbent assays; GM-CSF: granulocyte-macrophage colony-stimulating
factor; GMFI: geometric mean fluorescence intensity; HLA: human leukocyte
antigen; ICU: intensive care unit; IFN-γ: interferon gamma; IL-7: interleukin -7;
IQR: interquartile range; LPS: lipopolysaccharide; PD-L1: programmed cell
death ligand 1; PE: phycoerythrin; SD: standard deviation; SOFA: Sequential
Organ Failure Assessment; TNF-ɑ: tumor necrosis factor alpha
Acknowledgements
The authors thank Karen Steger-May with the Division of Biostatistics at
Washington University in St. Louis for her assistance with statistical analysis.
Funding
Anne Drewry was supported by the Foundation for Anesthesia Education
and Research and the Washington University Institute of Clinical and
Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the
National Center for Advancing Translational Sciences of the National
Institutes of Health (NIH). Enyo Ablordeppey was supported by the
Washington University School of Medicine Faculty Scholars grant and the
Foundation for Barnes-Jewish Hospital. Ellen Murray was supported by the
Foundation for Anesthesia Education and Research. Richard Hotchkiss and
Mark Hall receive funding from the NIH. Funding bodies played no role in
the design, data analysis, or interpretation of data for this study.
Availability of data and material
The datasets analyzed during the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
AD, RH, and MH conceived of the study and interpreted the results. AD
designed the study. AD, EA, EM, EB, and AW acquired the data. AD and RH
wrote the manuscript. All authors revised the manuscript and approved the
final version.
Competing interests
RH reports receiving grant support from MedImmune, GlaxoSmithKline,
Bristol-Myers Squibb, and Aurigene. AD, EA, EM, EB, AW, and MH declare that
they have no conflicts of interest.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Intuitional Review Board of Washington
University Human Research Protections Office. All participants or their legally
authorized representatives provided informed consent to participate in the
study.
Author details
1Department of Anesthesiology, Washington University School of Medicine,
660 S. Euclid, St. Louis, MO, USA. 2Departments of Anesthesiology and
Emergency Medicine, Washington University School of Medicine, St. Louis,
MO, USA. 3University of Missouri-Columbia School of Medicine, Columbia,
MO, USA. 4Department of Pediatrics, Critical Care Medicine, Nationwide
Children’s Hospital, The Ohio State University College of Medicine, Columbus,
OH, USA.
Received: 12 July 2016 Accepted: 26 September 2016
References
1. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. Lancet
Infect Dis. 2013;13:260–8.
2. Landelle C, Lepape A, Francais A, Tognet E, Thizy H, Voirin N, Timsit JF,
Monneret G, Vanhems P. Nosocomial infection after septic shock among
intensive care unit patients. Infect Control Hosp Epidemiol. 2008;29:1054–65.
3. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-
Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. Granulocyte-
macrophage colony-stimulating factor to reverse sepsis-associated
immunosuppression: a double-blind, randomized, placebo-controlled
multicenter trial. Am J Respir Crit Care Med. 2009;180:640–8.
4. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA.
Immunoparalysis and nosocomial infection in children with multiple organ
dysfunction syndrome. Intensive Care Med. 2011;37:525–32.
5. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C,
Bekker LG, Wood R, Harrison TS. Adjunctive interferon-gamma immunotherapy
for the treatment of HIV-associated cryptococcal meningitis: a randomized
controlled trial. AIDS. 2012;26:1105–13.
6. Squibb B-M. A phase 1b/2a, randomized, double-blinded, placebo-controlled,
multicenter study to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of BMS-936559 in subjects with severe sepsis. In: ClinicalTrials.
gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited April
20 2016]. Available from: https://clinicaltrials.gov/show/NCT02576457.
7. Revimmune. A multicenter, randomized, double-blinded, placebo-controlled
study of two dosing frequencies of recombinant interleukin-7 (CYT107)
treatment to restore absolute lymphocyte counts in sepsis patients. In:
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US);
2000. [cited April 20 2016]. Available from: https://clinicaltrials.gov/show/
NCT02640807.
8. Hamers L, Kox M, Pickkers P. Sepsis-induced immunoparalysis: mechanisms,
markers, and treatment options. Minerva Anestesiol. 2015;81:426–39.
9. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the
immune response in sepsis: a rational approach to administration of
immunoadjuvant therapies. Curr Opin Immunol. 2013;25:477–83.
10. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu
J, Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-
DR expression predicts mortality in septic shock. Intensive Care Med. 2006;32:
1175–83.
11. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P, Monneret
G. Low monocyte human leukocyte antigen-DR is independently associated with
nosocomial infections after septic shock. Intensive Care Med. 2010;36:1859–66.
12. Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B,
Payen D. Monocytic HLA-DR expression in intensive care patients: interest for
prognosis and secondary infection prediction. Crit Care Med. 2009;37:2746–52.
13. Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L,
Nicol K, Groner JI, Besner GE, Raffel C, Geyer S, El-Assal O, Hall MW. Innate
immune function predicts the development of nosocomial infection in
critically injured children. Shock. 2014;42:313–21.
14. Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J,
Shay DK, Nateri J, Greathouse K, Sullivan R, Tran T, Keisling S, Randolph AG,
Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, PSI
Flu Study Investigators. Innate immune function and mortality in critically ill
children with influenza: a multicenter study. Crit Care Med. 2013;41:224–36.
15. Flohe S, Lendemans S, Schade FU, Kreuzfelder E, Waydhas C. Influence of
surgical intervention in the immune response of severely injured patients.
Intensive Care Med. 2004;30:96–102.
16. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD,
Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma
treatment. Nat Med. 1997;3:678–81.
17. Piani A, Hossle JP, Birchler T, Siegrist CA, Heumann D, Davies G, Loeliger S,
Seger R, Lauener RP. Expression of MHC class II molecules contributes to
lipopolysaccharide responsiveness. Eur J Immunol. 2000;30:3140–6.
18. Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W,
Redl H, Roth E, Spittler A. Lipopolysaccharide-induced tumor necrosis factor
alpha production and not monocyte human leukocyte antigen-DR expression
is correlated with survival in septic trauma patients. Shock. 2006;25:129–34.
19. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,
Strobe Initiative. The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting observational
studies. Ann Intern Med. 2007;147:573–7.
Drewry et al. Critical Care  (2016) 20:334 Page 9 of 10
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal
SM, Vincent JL, Ramsay G, International Sepsis Definitions C. 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive
Care Med. 2003;29:530–8.
21. Demaret J, Walencik A, Jacob MC, Timsit JF, Venet F, Lepape A, Monneret G.
Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression
in clinical samples. Cytometry B Clin Cytom. 2013;84:59–62.
22. Wu JF, Ma J, Chen J, Ou-Yang B, Chen MY, Li LF, Liu YJ, Lin AH, Guan XD.
Changes of monocyte human leukocyte antigen-DR expression as a reliable
predictor of mortality in severe sepsis. Crit Care. 2011;15:R220.
23. Caille V, Chiche JD, Nciri N, Berton C, Gibot S, Boval B, Payen D, Mira JP,
Mebazaa A. Histocompatibility leukocyte antigen-D related expression is
specifically altered and predicts mortality in septic shock but not in other
causes of shock. Shock. 2004;22:521–6.
24. Ohno Y, Kitamura H, Takahashi N, Ohtake J, Kaneumi S, Sumida K, Homma
S, Kawamura H, Minagawa N, Shibasaki S, Taketomi A. IL-6 down-regulates
HLA class II expression and IL-12 production of human dendritic cells to
impair activation of antigen-specific CD4(+) T cells. Cancer Immunol
Immunother. 2016;65:193–204.
25. Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, Zhang Z, Dietz
AB, Porrata LF, Novak AJ, Liang AB, Yang ZZ, Ansell SM. IL-10 induces the
development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in
B-cell non-Hodgkin lymphoma. Blood Cancer J. 2015;5:e328.
26. Salgado FJ, Lojo J, Fernandez-Alonso CM, Vinuela J, Cordero OJ, Nogueira M.
Interleukin-dependent modulation of HLA-DR expression on CD4and CD8
activated T cells. Immunol Cell Biol. 2002;80:138–47.
27. van Vught LA, Wiewel MA, Hoogendijk AJ, Scicluna BP, Belkasim-Bohoudi H,
Horn J, Schultz MJ, van der Poll T. Reduced responsiveness of blood leukocytes
to lipopolysaccharide does not predict nosocomial infections in critically ill
patients. Shock. 2015;44:110–4.
28. De Gaudio AR, Rinaldi S, Chelazzi C, Borracci T. Pathophysiology of sepsis in the
elderly: clinical impact and therapeutic considerations. Curr Drug Targets. 2009;
10:60–70.
29. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU,
Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Monneret
G, Spittler A, Schmolke K, Reinke P, Volk HD, Kunz D. Monitoring temporary
immunodepression by flow cytometric measurement of monocytic HLA-DR
expression: a multicenter standardized study. Clin Chem. 2005;51:2341–7.
30. Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C,
Crozon J, Faure A, Guillaume C, Marcotte G, Vulliez A, Monneuse O,
Monneret G. Lack of recovery in monocyte human leukocyte antigen-DR
expression is independently associated with the development of sepsis
after major trauma. Crit Care. 2010;14:R208.
31. Segre E, Fullerton JN. Stimulated whole blood cytokine release as a biomarker of
immunosuppression in the critically ill: the need for a standardized methodology.
Shock. 2016;45:490–4.
32. Dubravec DB, Spriggs DR, Mannick JA, Rodrick ML. Circulating human peripheral
blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc Natl
Acad Sci U S A. 1990;87:6758–61.
33. Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed death
ligand-1 expression after 3-4 days of sepsis is associated with risk stratification
and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20:124.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Drewry et al. Critical Care  (2016) 20:334 Page 10 of 10
